Document is current

Article History

Received: 12 December 2025

Revised: 22 April 2026

Accepted: 17 May 2026

First Online: 13 June 2026

Compliance with ethical standards

:

: The scientific guarantor of this publication is Tali Amir, MD, at Memorial Sloan Kettering Cancer Center.

: The authors of this manuscript declare relationships with the following companies: Tali Amir is a site PI for the CEM Imaging Screening Trial (CMIST), which is funded by the American College of Radiology and GE Healthcare, and also reports honorarium from Private Medical. Sarah Eskreis-Winkler reports being a consultant for Medscape. Molly P. Hogan is the PI of a study funded by Aura Technologies. Maxine S. Jochelson reports being a consultant for GE. Christopher E. Comstock reports being a consultant for Bayer Medical and Recentric Healthcare Technologies. Janice S. Sung reports being a consultant for GE and Hologic. The remaining authors declare no conflict of interest.

: Varadan Sevilimedu, MBBS, DrPH, at Memorial Sloan Kettering Cancer Center, kindly provided statistical advice for this manuscript.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained.

: Patients in our study overlapped with prior retrospective studies as follows: 155 patients overlapped with Nissan et al.’s study on the sensitivity and specificity of CEM in extremely dense breasts [ ], 71 patients overlapped with Coffey et al.’s study [ ] on the utility of short-term follow-up of CEM lesions after a negative MRI, and 10 patients overlapped with Hogan et al.’s study on the role of CEM in patients with a history of lobular neoplasia [ ]. In addition, 9 patients overlapped with Horvat et al.’s prospective study [ ] on the role of supplemental whole-breast ultrasound with CEM.

: